SCHEMBL447586

SCHEMBL447586

O=C([O-])C(F)(F)C(F)(F)F.[Na+]

nearest known ligand 0.40

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA4 known ✓ P22748 4/20 0.35
CA1 known ✓ P00915 1/20 0.33
THRB known ✓ P10828 1/20 0.33
FAHD1 Q6P587 1/20 0.35
CASP1 P29466 1/20 0.35
MEN1 O00255 1/20 0.30
LDHA P00338 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL5963065 0.93 THRB (0.33) THRB
SCHEMBL6843550 0.93 THRB (0.33) THRB
SCHEMBL15750747 0.93 THRB (0.33) THRB
SCHEMBL6848298 0.93 THRB (0.33) THRB
Silver SCHEMBL621693 0.93 THRB (0.33) THRB
SCHEMBL3693055 0.93 THRB (0.33) THRB
Zinc Ion SCHEMBL4581329 0.93 THRB (0.33) THRB
Potassium Ion SCHEMBL1094505 0.93 CA4 (0.35) CA4FAHD1THRBMEN1LDHA
SCHEMBL22598039 0.93 THRB (0.33) THRB
SCHEMBL8409591 0.93 THRB (0.33) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117886666-A Preparation method of tetrafluoroethylene 上海州达洋半导体材料有限公司 2024-04-16 CN claimed
CN-114560903-B Preparation method of abiraterone derivative and cytotoxicity evaluation thereof 绍兴市上虞区武汉理工大学高等研究院 2023-08-01 CN claimed
CN-113563337-B Preparation method of camelning alkali A 武汉理工大学 2023-07-04 CN claimed
CN-112852475-B Fluorine-containing demulsifying compound and demulsifier for oil field 天津长芦新材料研究院有限公司 2023-02-28 CN claimed
CN-114560903-A Simple preparation method of abiraterone derivative and cytotoxicity evaluation of abiraterone derivative 绍兴市上虞区武汉理工大学高等研究院 2022-05-31 CN claimed
CN-113563337-A Simple preparation method of camelinine A 武汉理工大学 2021-10-29 CN claimed
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 US claimed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 EP claimed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 WO claimed
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-04-16 US disclosed
EP-4657572-A1 COMPOSITION, ELECTROCHEMICAL DEVICE BINDER, ELECTRODE MIXTURE, ELECTRODE, AND SECONDARY BATTERY Daikin Industries, Ltd. (JP) 2025-12-03 EP disclosed
US-20250349897-A1 ELECTROLYTIC SOLUTION, AND ELECTROCHEMICAL DEVICE AND SECONDARY BATTERY USING SAME DAIKIN INDUSTRIES, LTD. (JP) 2025-11-13 US disclosed
WO-2025224604-A2 ALKYLPHOSPHONIUM-FUNCTIONALIZED ION EXCHANGE RESINS 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-10-30 WO disclosed
US-12456760-B2 Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2025-10-28 US disclosed
WO-1991019708-A1 NEW THIOPHENE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-26 WO disclosed
US-5021412-A Protecting agricultural crops MITSUI TOATSU CHEMICALS, INC. (JP) 1991-06-04 US disclosed
EP-0396250-A1 Pyrimidinone derivatives ZENECA LIMITED (GB) 1990-11-07 EP disclosed
EP-0376524-A1 Benzopyran and related compounds BEECHAM GROUP PLC (GB) 1990-07-04 EP disclosed
EP-0354297-A1 Thiadiazines, process for production thereof, and insecticidal and acaricidal agents comprising the thiadiazines MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-02-14 EP disclosed
EP-0321175-A1 Indane derivatives BEECHAM GROUP PLC (GB) 1989-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12456760-B2 Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery NHERF1, NAP1L1, NAF1 CA4 557/4885CA1 68/4885THRB 4320/4885
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES CBR3, CYCS, CBR1 CA4 2045/4885CA1 2974/4885THRB 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.